Reduced expression of the ATP2A2 gene in vemurafenib-induced keratoacanthoma-like papules in a melanoma patient.
Department of Dermatology, Tokyo Medical University, Tokyo, Japan.
Hiroko
H
Wakimoto
Department of Dermatology, Tokyo Medical University, Tokyo, Japan.
Kazutoshi
K
Harada
Department of Dermatology, Tokyo Medical University, Tokyo, Japan.
Takashi
T
Arai
Department of Dermatology, Tokyo Medical University, Tokyo, Japan.
Tatsuo
T
Maeda
Department of Dermatology, Tokyo Medical University, Tokyo, Japan.
Ryokichi
R
Irisawa
Department of Dermatology, Tokyo Medical University, Tokyo, Japan.
Ryoji
R
Tsuboi
D000051:Acantholysis / Q000139:chemically induced / Q000473:pathology; D000970:Antineoplastic Agents / Q000009:adverse effects*; D005148:Facial Dermatoses / Q000139:chemically induced / Q000235:genetics / Q000473:pathology; D005260:Female; D015870:Gene Expression; D006801:Humans; D007211:Indoles / Q000009:adverse effects*; D007636:Keratoacanthoma / Q000139:chemically induced* / Q000235:genetics* / Q000473:pathology; D008545:Melanoma / Q000188:drug therapy*; D008875:Middle Aged; D053498:Sarcoplasmic Reticulum Calcium-Transporting ATPases / Q000235:genetics*; D012878:Skin Neoplasms / Q000188:drug therapy*; D013449:Sulfonamides / Q000009:adverse effects*; D000077484:Vemurafenib
D000970:Antineoplastic Agents; D007211:Indoles; D013449:Sulfonamides; D000077484:Vemurafenib; D053498:Sarcoplasmic Reticulum Calcium-Transporting ATPases; C506946:ATP2A2 protein, human